https://t.co/gIJ1QwuupC

Congrats to the Vividion team on a KEAP1 binder which unexpectedly turned out to be a KEAP1/CUL3 molecular glue to degrade NRF2. Unexpected activity since known binders inhibit KEAP1 rather than activate. Kudos to sticking with the data and expecting the unexpected! link below

Doing good science is 90% finding a science buddy to constantly talk to about the project.

Your welcome! Hope your well

The Biotech Leaders Handbook by Angelos Georgakis. A wonderful summary of so many biotech leadership and fundraising books and interviews with leaders in the space. Great set of cliff notes, with wide ranging topics from managing conflict to raising money. Enjoy! 5/5

Hard Thing About Hard things by Ben Horowitz. Best encapsulation of the vision, dedication, and perseverance that a founder needs to have to be successful. Written for tech, but this vital information is applicable in any industry 4/5

For Blood and Money by Nathan Vardi. Illustrates the unpredictability, risk, reward and thrilling nature of the business of biotech. Chaos is a norm in this industry because so little is known about what will actually work in the clinic! 3/5

First up Emperor of All Maladies by Siddharta Mukherjee. Amazingly written and captivating piece of the history of mankind’s battle with cancer. For me, so elegantly put our research into a broader context that it inspired me to double down my focus on cancer therapies 2/5

I have benefited greatly from some amazing books that helped define my approach to science, startups and leadership. Delighted to pass them on! 1/5

A feature in @NatureBiotech discusses the rise in team size in academic science and how it has generated an unintended side effect: junior scientists are less likely to secure research funding or obtain tenure and are more likely to leave academia. 🔒

Congrats to Mauricio Jacobo Jacobo and Hayley Donnella who drove the project and have both moved on from the lab and thanks to our wonderful collaborator @AndreiGoga_SF @UCSFCancer

We also found in vivo and clinical evidence that cGAS signaling leads to poorer outcomes in breast cancer treated with chemo

We found a genomically unstable sub population in breast cancers where increased cGAS/STING signaling causes them to persist and cause resistance to chemotherapies.

In what started as a control experiment we were surprised to find transcriptional heterogeneity even in cancer cell lines, in ways that make certain subpopulations resistant to standard of care tx.

Its been thrilling to see Rezo hitting its stride in mapping networks, prosecuting targets and drilling into drug discovery. Amazing things to come. We are excited to build the NextGen Sequence->Systems->Structures->Drugs platform!

Great department and wonderful place to start your career!

Excited about the future of Rezo with such a seasoned and balanced leader at the helm, onwards!

We're excited to welcome Nadir Mahmood, Ph.D., as CEO and board member! His expertise will play a pivotal role as we seek to shift the way we understand disease biology through our integrated mapping of disease networks for precision therapeutics. https://t.co/NwrdYyLNIs

New work from our group delineating biomarkers and indications for Rapalink, originally from @kevansf, now in the clinic with Revolution Medicines. This amazing Frankenstein-molecule can overcome acquired resistance to hormone tx and cdk4/6 inhibitors in ER+ breast cancers

The fact that ADCs do not appear to require expression of the target antigen is a pet peeve of mine for years - new evidence that’s it’s effect is non specific and basically slow release chemo